FDA Approval: RANLUSPEC (RANIBIZUMAB-HKDZ) — Type 2 - New Active Ingredient
Policy FDA-BLA761480 · Ophthalmology
The billing pathway for RANLUSPEC cannot be determined until the FDA label publishes. Billing teams should verify against the label for the final route of administration and associated billing details